CG Oncology
CGON
62.38
-1.26
-1.98%
CG Oncology
US · CGON
#1929 by market cap
Listed 2024
62.38
-1.26
-1.98%
Live - 5344 symbols - heartbeat 29s ago
· 2026-10-08 09:08
Pre-market
61.00
-2.21%
After-hours
62.38
0.00%
- Market cap
- 5.53B
- P/E (TTM)i
- -23.19
- P/Bi
- 5.37
- EPSi
- -2.08
- Div yieldi
- 0.00%
- 52W posi
- 59%
Reader sentiment
Are you bullish or bearish on CGON?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 10 analysts
Buy
Avg price target
92.56 +48.4%
Price target rangecurrent 62.38
Low79.00
Avg92.56
High108.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-10 | Truist Financial | -- | BUY | -- |
| 2026-08-21 | UBS | -- | BUY | 90.00 |
| 2026-08-20 | UBS | -- | BUY | 90.00 |
| 2026-08-17 | Morgan Stanley | -- | BUY | 93.00 |
| 2026-08-11 | Truist Financial | -- | BUY | 85.00 |
| 2026-08-07 | LifeSci Capital | -- | BUY | 108.00 |
| 2026-08-07 | Piper Sandler | -- | BUY | 85.00 |
| 2026-08-07 | BofA Securities | -- | BUY | 88.00 |
| 2026-08-07 | Truist Financial | -- | BUY | 85.00 |
| 2026-08-07 | H.C. Wainwright | -- | BUY | 100.00 |
| 2026-08-06 | Cantor Fitzgerald | -- | BUY | 105.00 |
| 2026-08-06 | JonesTrading | -- | BUY | 85.00 |
| 2026-08-06 | H.C. Wainwright | -- | BUY | 100.00 |
| 2026-08-06 | RBC Capital | -- | BUY | 79.00 |
| 2026-07-29 | H.C. Wainwright | -- | BUY | 100.00 |
| 2026-07-28 | LifeSci Capital | -- | BUY | 108.00 |
| 2026-07-09 | Truist Financial | -- | BUY | -- |
| 2026-06-30 | RBC Capital | -- | BUY | 81.00 |
| 2026-06-23 | Piper Sandler | -- | BUY | 82.00 |
| 2026-06-16 | JonesTrading | -- | BUY | 85.00 |
| 2026-05-27 | Truist Financial | -- | BUY | -- |
| 2026-05-26 | Wolfe Research | -- | HOLD | -- |
| 2026-05-26 | BofA Securities | -- | BUY | 87.00 |
| 2026-05-19 | Wolfe Research | -- | HOLD | -- |
| 2026-05-18 | Truist Financial | -- | BUY | -- |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 09:08:44 · For reference only, not investment advice and not tailored to your situation.